Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMTM safety and tolerability study in mild to moderate Alzheimer's disease on background AChEI and/or memantine
2011-005292-17Phase 2Terminated
- Sponsor
- TauRx Therapeutics Ltd
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydromethylthionine mesylate in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started May 2012; status: terminated.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-005292-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005292-17.